These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 25411597)

  • 61. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study.
    Nishimura R; Tanaka Y; Koiwai K; Inoue K; Hach T; Salsali A; Lund SS; Broedl UC
    Cardiovasc Diabetol; 2015 Jan; 14():11. PubMed ID: 25633683
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Increased urine output by ipragliflozin in a non-diabetic patient with a diuretic-resistant heart failure.
    Sairaku A; Nakano Y; Kihara Y
    Int J Cardiol; 2015 Feb; 180():42-3. PubMed ID: 25438206
    [No Abstract]   [Full Text] [Related]  

  • 63. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.
    Del Prato S; Nauck M; Durán-Garcia S; Maffei L; Rohwedder K; Theuerkauf A; Parikh S
    Diabetes Obes Metab; 2015 Jun; 17(6):581-590. PubMed ID: 25735400
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study.
    Iemitsu K; Iizuka T; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Kawata T; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyagi S; Hoshino K; Ishikawa M; Obana M; Sasai N; Kaneshige H; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2016 May; 8(5):373-8. PubMed ID: 27081422
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
    Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
    Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
    Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
    J Pharmacol Sci; 2016 Mar; 130(3):159-69. PubMed ID: 26970780
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.
    Iizuka T; Iemitsu K; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Kawata T; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyagi S; Hoshino K; Ishikawa M; Matsuzawa Y; Obana M; Sasai N; Kaneshige H; Minagawa F; Saito T; Shinoda K; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2016 Mar; 8(3):267. PubMed ID: 26858805
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Glycosuria medicated with ipragliflozin and nifedipine or ipragliflozin and candesartan: a case report.
    Okada S; Shibusawa R; Tagaya Y; Saito T; Yamada E; Shimoda Y; Satoh T; Okada J; Yamada M
    J Med Case Rep; 2014 Dec; 8():428. PubMed ID: 25515334
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
    Scheen AJ
    Clin Pharmacokinet; 2015 Jul; 54(7):691-708. PubMed ID: 25805666
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study.
    Heise T; Mattheus M; Woerle HJ; Broedl UC; Macha S
    Clin Ther; 2015 Apr; 37(4):793-803. PubMed ID: 25636696
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes.
    Lewin A; DeFronzo RA; Patel S; Liu D; Kaste R; Woerle HJ; Broedl UC
    Diabetes Care; 2015 Mar; 38(3):394-402. PubMed ID: 25633662
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Pharmacological and clinical profile of ipragliflozin (Suglat®): a new therapeutic agent for type 2 diabetes].
    Takasu T; Takakura S; Kaku S
    Nihon Yakurigaku Zasshi; 2015 Jan; 145(1):36-42. PubMed ID: 25743234
    [No Abstract]   [Full Text] [Related]  

  • 73. Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers.
    Kinoshita S; Kondo K
    Expert Opin Drug Metab Toxicol; 2015 Jan; 11(1):7-14. PubMed ID: 25424014
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
    Davidson JA; Kuritzky L
    Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.
    Neal B; Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Ways K; Desai M; Shaw W; Capuano G; Alba M; Jiang J; Vercruysse F; Meininger G; Matthews D;
    Diabetes Care; 2015 Mar; 38(3):403-11. PubMed ID: 25468945
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Accelerated intestinal glucose absorption in morbidly obese humans: relationship to glucose transporters, incretin hormones, and glycemia.
    Nguyen NQ; Debreceni TL; Bambrick JE; Chia B; Wishart J; Deane AM; Rayner CK; Horowitz M; Young RL
    J Clin Endocrinol Metab; 2015 Mar; 100(3):968-76. PubMed ID: 25423571
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy.
    Yamamoto C; Miyoshi H; Ono K; Sugawara H; Kameda R; Ichiyama M; Yamamoto K; Nomoto H; Nakamura A; Atsumi T
    Endocr J; 2016 Jun; 63(6):589-96. PubMed ID: 27052123
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence.
    Scheen AJ; Paquot N
    Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S4-S11. PubMed ID: 25554070
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats.
    Hayashizaki-Someya Y; Kurosaki E; Takasu T; Mitori H; Yamazaki S; Koide K; Takakura S
    Eur J Pharmacol; 2015 May; 754():19-24. PubMed ID: 25701721
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus.
    Liakos A; Karagiannis T; Bekiari E; Boura P; Tsapas A
    Ther Adv Endocrinol Metab; 2015 Apr; 6(2):61-7. PubMed ID: 25941564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.